INNATE PHARMA

Innate Pharma is a clinical-stage biotechnology company specialized in immuno-oncology and dedicated to improving cancer treatment through innovative therapeutic antibodies that exploit the immune system. Innate Pharma's broad antibody portfolio includes several potential «first-in-class» candidates in clinical and preclinical stages in cancers with high medical need. Innate Pharma is a pioneer in the understanding of NK cell biology and has developed expertise in the tumor microenvironment and tumor antigens, as well as in antibody engineering. Its innovative approach has enabled it to build a diversified proprietary portfolio and to forge alliances with leading biopharmaceutical companies such as Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi as well as a multi-product partnership with AstraZeneca. Revenues break down by source of income as follows:

- government financing for research expenditure (51%);

- revenues from collaboration and licensing agreements (49%);

At the end of 2021, the company held a portfolio of 6 products in clinical development including 1 in phase III (Monalizumab for the treatment of cancer), 2 in phase II (Lacutamab for the treatment of cutaneous T-cell lymphoma and IPH4102 for the treatment of bullous pemphigoid) and 3 in phase I (IPH5401 and IPH5301 for the treatment of solid tumors, and IPH6101 for the treatment of relapsed or refractory acute myeloid leukemia), and 7 in preclinical development phase.